Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2715205 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL27946874 | 1.00 | SLC1A3 (0.41) | — | |
| Hydrochloric Acid SCHEMBL373444 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28240750 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL28240747 | 0.97 | — | — | |
| SCHEMBL427317 | 0.97 | — | — | |
| SCHEMBL31470932 | 0.97 | — | — | |
| SCHEMBL428684 | 0.97 | — | — | |
| SCHEMBL427318 | 0.97 | — | — | |
| SCHEMBL28141431 | 0.97 | SLC1A3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119570870-A | Method for synthesizing L-2-aminobutyric acid and L-2-aminobutanamide hydrochloride and application | 浙江永太科技股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-118324681-A | Salicylic acid(s) -alpha-ethyl-2-oxo-1-pyrrolidine acetamide and crystal structure thereof | 浙江理工大学 | 2024-07-12 | — | — | CN | claimed |
| CN-118255704-A | Synthesis method of levetiracetam | 浙江江北药业有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118221541-A | Preparation method of (S) - (+) -2-aminobutanamide hydrochloride | 浙江华海药业股份有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-117229164-A | Synthesis method of 2-aminobutanamide | 国药集团化学试剂有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-112154140-B | Compound and application thereof in synthesizing Brivaracetam (Brivaracetam) bulk drug | 福建海西新药创制股份有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-114213305-B | Production process of brivaracetam | 苏州诚和医药化学有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-116500151-A | HPLC analysis method for (S) -2-aminobutanamide hydrochloride related substances | 杭州华东医药集团浙江华义制药有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-113582903-B | Method for synthesizing medicine for treating epilepsy by using L-2-aminobutanamide hydrochloride | 沧州那瑞化学科技有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-109553549-B | Preparation of (S) -N- (1-amino-1-oxybutan-2-yl) -4-hydroxybutyramide | 万特制药(海南)有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-101684078-A | Chemical synthesis method for of 2-amino-butanamide hydrochloride | UNIV ZHEJIANG TECHNOLOGY | 2010-03-31 | — | — | CN | claimed |
| US-7531673-B2 | Preparation of amino acid amides | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-05-12 | — | — | US | claimed |
| CN-101130504-A | Synthesis, split and racemization of chirality medicament levetiracetam midbody (S)-(+)-2-amido butyramide hydrochlorate | ABA CHEMICALS LTD (CN) | 2008-02-27 | — | — | CN | claimed |
| US-7132552-B2 | Process for producing levetiracetam | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-11-07 | — | — | US | claimed |
| CN-1802352-A | Process for the preparation of levetiracetam | TEVA PHARMA (IL) | 2006-07-12 | — | — | CN | claimed |
| EP-1566376-A1 | Preparation of amino acid amides | Dr. Reddy's Laboratories Limited (IN) | 2005-08-24 | — | — | EP | claimed |
| US-20050182262-A1 | Preparation of amino acid amides | DR. REDDY'S LABORATORIES, LIMITED (IN) | 2005-08-18 | — | — | US | claimed |
| EP-1517893-A2 | PROCESS FOR PRODUCING LEVETIRACETAM | Teva Pharmaceutical Industries Limited (IL) | 2005-03-30 | — | — | EP | claimed |
| US-20040259933-A1 | Process for producing levetiracetam | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-12-23 | — | — | US | claimed |
| WO-2004069796-A2 | PROCESS FOR PRODUCING LEVETIRACETAM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-19 | — | — | WO | claimed |